Cannabis-Like drugs may unlock diabetes secrets
NCT ID NCT01517100
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two drugs that act on the body's endocannabinoid system—nabilone and CP-945,598—to see how they affect insulin production and sensitivity. Forty-five healthy men aged 21 to 55 took part in four visits, each receiving a different drug combination. The goal was to better understand how this system regulates insulin, which could lead to new diabetes treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nabilone and CP-945,598
What this could lead to
If successful, this could point toward new treatment approaches for type 2 diabetes by targeting the endocannabinoid system.
What could go wrong
This is a small, early-phase study in healthy men, not people with diabetes. Results may not translate to real-world treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States